Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

301 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.
Ohmachi K, Niitsu N, Uchida T, Kim SJ, Ando K, Takahashi N, Takahashi N, Uike N, Eom HS, Chae YS, Terauchi T, Tateishi U, Tatsumi M, Kim WS, Tobinai K, Suh C, Ogura M. Ohmachi K, et al. Among authors: chae ys. J Clin Oncol. 2013 Jun 10;31(17):2103-9. doi: 10.1200/JCO.2012.46.5203. Epub 2013 May 6. J Clin Oncol. 2013. PMID: 23650408 Clinical Trial.
Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu/Cy/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma.
Kim JG, Sohn SK, Chae YS, Yang DH, Lee JJ, Kim HJ, Shin HJ, Jung JS, Kim WS, Kim DH, Suh C, Kim SJ, Eom HS, Bae SH. Kim JG, et al. Among authors: chae ys. Bone Marrow Transplant. 2007 Nov;40(10):919-24. doi: 10.1038/sj.bmt.1705841. Epub 2007 Sep 10. Bone Marrow Transplant. 2007. PMID: 17846602
Prognostic factors and clinical outcomes of high-dose chemotherapy followed by autologous stem cell transplantation in patients with peripheral T cell lymphoma, unspecified: complete remission at transplantation and the prognostic index of peripheral T cell lymphoma are the major factors predictive of outcome.
Yang DH, Kim WS, Kim SJ, Bae SH, Kim SH, Kim IH, Yoon SS, Mun YC, Shin HJ, Chae YS, Kwak JY, Kim H, Kim MK, Kim JS, Won JH, Lee JJ, Suh CW. Yang DH, et al. Among authors: chae ys. Biol Blood Marrow Transplant. 2009 Jan;15(1):118-25. doi: 10.1016/j.bbmt.2008.11.010. Biol Blood Marrow Transplant. 2009. PMID: 19135950 Free article.
Pulmonary marginal zone B-cell lymphoma of MALT type--what is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) study.
Oh SY, Kim WS, Kim JS, Kim SJ, Kwon HC, Lee DH, Won JH, Hwang IG, Kim MK, Lee SI, Chae YS, Yang DH, Lee GW, Choi CW, Park J, Suh C, Kim HJ. Oh SY, et al. Among authors: chae ys. Ann Hematol. 2010 Jun;89(6):563-8. doi: 10.1007/s00277-009-0875-7. Epub 2009 Dec 19. Ann Hematol. 2010. PMID: 20024551
Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study.
Yhim HY, Kang HJ, Choi YH, Kim SJ, Kim WS, Chae YS, Kim JS, Choi CW, Oh SY, Eom HS, Kim JA, Lee JH, Won JH, Shim H, Lee JJ, Sung HJ, Kim HJ, Lee DH, Suh C, Kwak JY. Yhim HY, et al. Among authors: chae ys. BMC Cancer. 2010 Jun 22;10:321. doi: 10.1186/1471-2407-10-321. BMC Cancer. 2010. PMID: 20569446 Free PMC article.
Stage IV marginal zone B-cell lymphoma--prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study.
Oh SY, Kim WS, Kim JS, Kim SJ, Lee S, Lee DH, Won JH, Hwang IG, Kim MK, Lee SI, Chae YS, Yang DH, Kang HJ, Choi CW, Park J, Kim HJ, Kwon JH, Lee HS, Lee GW, Eom HS, Kwak JY, Suh C, Kim HJ. Oh SY, et al. Among authors: chae ys. Cancer Sci. 2010 Nov;101(11):2443-7. doi: 10.1111/j.1349-7006.2010.01698.x. Cancer Sci. 2010. PMID: 20831770 Free PMC article.
Multiple mucosa-associated lymphoid tissue organs involving marginal zone B cell lymphoma: organ-specific relationships and the prognostic factors. Consortium for improving survival of lymphoma study.
Oh SY, Kim WS, Kim JS, Kim SJ, Lee S, Lee DH, Won JH, Hwang IG, Kim MK, Lee SI, Chae YS, Yang DH, Kang HJ, Choi CW, Park J, Kim HJ, Kwon JH, Lee HS, Lee GW, Eom HS, Kwak JY, Lee WS, Suh C, Kim HJ. Oh SY, et al. Among authors: chae ys. Int J Hematol. 2010 Oct;92(3):510-7. doi: 10.1007/s12185-010-0680-z. Epub 2010 Sep 14. Int J Hematol. 2010. PMID: 20838958
Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the Consortium for Improving Survival of Lymphoma.
Kang BW, Sohn SK, Moon JH, Chae YS, Kim JG, Lee SJ, Kim WS, Lee JJ, Lee SR, Park KU, Lee HS, Lee WS, Won JH, Park MR, Kwak JY, Kim MK, Kim HJ, Oh SY, Kang HJ, Suh C. Kang BW, et al. Among authors: chae ys. Blood Res. 2014 Mar;49(1):15-21. doi: 10.5045/br.2014.49.1.15. Epub 2014 Mar 24. Blood Res. 2014. PMID: 24724062 Free PMC article.
Clinical Outcomes and Prognostic Factors of Up-Front Autologous Stem Cell Transplantation in Patients with Extranodal Natural Killer/T Cell Lymphoma.
Yhim HY, Kim JS, Mun YC, Moon JH, Chae YS, Park Y, Jo JC, Kim SJ, Yoon DH, Cheong JW, Kwak JY, Lee JJ, Kim WS, Suh C, Yang DH; Consortium for Improving Survival of Lymphoma Study. Yhim HY, et al. Among authors: chae ys. Biol Blood Marrow Transplant. 2015 Sep;21(9):1597-604. doi: 10.1016/j.bbmt.2015.05.003. Epub 2015 May 8. Biol Blood Marrow Transplant. 2015. PMID: 25963920 Free article. Clinical Trial.
A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial.
Oh SY, Kim WS, Kim JS, Chae YS, Lee GW, Eom HS, Ryoo HM, Lee S, Kim SJ, Yoon DH, Won JH, Hong J, Park J, Lee SM, Hong JY, Park E, Kim HJ, Yang DH, Kim HJ, Suh C. Oh SY, et al. Among authors: chae ys. Leuk Lymphoma. 2016;57(6):1406-12. doi: 10.3109/10428194.2015.1099650. Epub 2015 Nov 16. Leuk Lymphoma. 2016. PMID: 26413982 Clinical Trial.
301 results